DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Implementation Strategies for Monitoring Adherence in Real Time

Not Applicable

Active, not recruiting

Conditions: Symptoms and Signs
Lung Cancer
Medication Adherence

Interventions: Other: Usual Care
Device: Conversational Agent/Chatbot

First Posted Date: 2020-04-15

Last Posted Date: 2025-01-17

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 75

Registration Number: NCT04347161

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

CapTemY90 for Grade 2 NET Liver Metastases

Phase 2

Recruiting

Conditions: Neuroendocrine Tumors
Neuroendocrine Tumor Grade 2

Interventions: Drug: Capecitabine Oral Product
Drug: Temozolomide Oral Product
Combination Product: transarterial radioembolization

First Posted Date: 2020-04-08

Last Posted Date: 2024-11-01

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 50

Registration Number: NCT04339036

Locations: 🇺🇸
UC San Diego, La Jolla, California, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Ramucirumab

First Posted Date: 2020-04-02

Last Posted Date: 2025-01-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 59

Registration Number: NCT04332367

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Behavioral Relaxation Approaches for Insomnia in Lung Cancer Patients

Not Applicable

Withdrawn

Conditions: Insomnia

Interventions: Behavioral: Assisted Relaxation Therapy
Behavioral: Modified Assisted Relaxation Therapy

First Posted Date: 2020-03-23

Last Posted Date: 2024-11-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT04318249

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated with Chemoradiation Therapy

Conditions: Lung Cancer Stage III
Lung Cancer Stage II
Cardiotoxicity
Radiation Toxicity

Interventions: Other: Chemoradiation

First Posted Date: 2020-03-12

Last Posted Date: 2024-10-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 221

Registration Number: NCT04305613

Locations: 🇺🇸
Rutger's University / Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
The Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Lancaster General Hospital, Lancaster, Pennsylvania, United States

and more 5 locations

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer with DNA Repair Defects

Phase 2

Completed

Conditions: Prostate Adenocarcinoma

Interventions: Drug: Niraparib Pill

First Posted Date: 2020-02-28

Last Posted Date: 2024-11-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 12

Registration Number: NCT04288687

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

GeoScan and Remote Geo Smoking Study: Neural and Behavioral Correlates of Smokers' Exposure to Retail Environments

Not Applicable

Completed

Conditions: Smoking, Tobacco
Smoking
Smoking, Cigarette

Interventions: Behavioral: 7-11
Behavioral: CVS

First Posted Date: 2020-02-21

Last Posted Date: 2024-10-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 336

Registration Number: NCT04279483

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Penn Biobank Return of Research Results Program

Not Applicable

Completed

Conditions: Hereditary Cancer
Cancer
Hereditary Cardiac Amyloidosis
Cardiovascular Diseases

Interventions: Behavioral: e-Health (web-based) disclosure portal
Behavioral: Provider mediated disclosure

First Posted Date: 2020-01-27

Last Posted Date: 2024-07-01

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 260

Registration Number: NCT04242667

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Phase 2

Withdrawn

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Pegvorhyaluronidase alfa
Drug: Abraxane
Drug: Gemcitabine

First Posted Date: 2019-10-22

Last Posted Date: 2020-01-31

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT04134468

Locations: 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States

Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant

Completed

Conditions: Atrial Fibrillation
Hematopoietic Stem Cell Transplant
Atrial Flutter

Interventions: Other: HSCT Patients

First Posted Date: 2019-10-08

Last Posted Date: 2024-10-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 21

Registration Number: NCT04118530

Locations: 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy